Abstract:Objective: To observe the antioxidative effects of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors (NAY) in vitro and in vivo models of hyperuricemia and explore the mechanism. Methods: A classical experimental method of acute toxicity and a chronic toxicity test were used to compare the toxic effects of different doses of NAY in mice. The hyperuricemia mouse model was established by gavage of potassium oxonate in vivo . After treatment with different doses of NAY (low dose: 10 mg/kg, medium dose: 20 mg/kg, and high dose: 40 mg/kg) and allopurinol (positive drug, 10 mg/kg), observe the levels of uric acid (UA), creatinine (CRE), and urea nitrogen (BUN) in urine and serum, respectively, and detect the activities of xanthine oxidase in the liver. The hyperuricemia cell model was induced by adenosine and xanthine oxidase in vitro . The cells were given different doses of NAY (50, 100, and 200 μmol/L) and allopurinol (100 μmol/L). Then the culture supernatant UA level of the medium was measured. The next step was to detect the xanthine oxidase activity in the liver and AML12 cells, and the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammatory factors in the kidney and serum of mice. Western blot was used to detect xanthine oxidase protein expression in mouse liver tissue and AML12 cells, ASC, Caspase-1, NLRP3, GLUT9, OAT1, and OAT3 protein expression in mouse kidney tissue and HK-2 cells. Hematoxylin–eosin staining was used to stain the liver and kidney tissues of mice and observe the tissue lesions. Results: NAY had little effect on blood routine and biochemical indexes of mice, but significantly reduced the serum UA level. NAY significantly reduced the level of UA in hyperuricemia mice and cells by inhibiting xanthine oxidase activity and reduced the levels of TNF-α, IL-6, and other inflammatory factors in serum and kidney of mice. NAY can inhibit inflammation by inhibiting the NLRP3 pathway. In addition, NAY can downregulate GLUT9 protein expression and upregulate OAT1 and OAT3 protein expression to reduce the UA level by promoting UA excretion and inhibiting UA reabsorption. Conclusion: These findings suggested that NAY produced dual hypouricemic actions. On the one hand, it can inhibit the formation of UA by inhibiting xanthine oxidase inhibitors activity, and on the other hand, it can promote the excretion of UA by regulating the UA transporter. It provides new ideas for the development of hyperuricemia drugs in the future.

In Vitro Xanthine Oxidase Inhibitory and in Vivo Anti-Hyperuricemic Properties of Sodium Kaempferol-3′-sulfonate

Novel Insights into the Inhibitory Mechanism of Kaempferol on Xanthine Oxidase.

Xanthine oxidase inhibitors: Virtual screening and mechanism of inhibition studies

Screening and Evaluation of Flavonoids As Xanthine Oxidase Inhibitors for Reducing Uric Acid Through Combined Cell Biology and Molecular Simulation

Natural Xanthine Oxidase Inhibitor 5-O-Caffeoylshikimic Acid Ameliorates Kidney Injury Caused by Hyperuricemia in Mice

In Vitro and in Silico Xanthine Oxidase Inhibitory Activity of Selected Phytochemicals Widely Present in Various Edible Plants.

Identification of Natural Xanthine Oxidase Inhibitors: Virtual Screening, Anti-Xanthine Oxidase Activity, and Interaction Mechanism.

Design, Synthesis and Biological Evaluation of Novel Xanthine Oxidase Inhibitors Bearing a 2-Arylbenzo[b]furan Scaffold

Identification of a novel xanthine oxidoreductase inhibitor for hyperuricemia treatment with high efficacy and safety profile

A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective

Hesperetin Inhibits Xanthine Oxidase Activity via Altering the Protein’s Secondary Structure and Suppressing Superoxide Anion Generation

Design, synthesis, and evaluation of chalcone derivatives as xanthine oxidase inhibitors

Molecular Dockings and Molecular Dynamics Simulations Reveal the Potency of Different Inhibitors Against Xanthine Oxidase

Anti-hyperuricemia Activity and Toxicity Prediction of a Novel Xanthine Oxidoreductase Inhibitor.

Design, synthesis and biological evaluation of N-(4-alkoxy-3-(1H-tetrazol-1-yl)phenyl) heterocyclic aromatic amide derivatives as xanthine oxidase inhibitors

Inhibitiory Mechanism of Phloretin on Xanthine Oxidase and Its Synergistic Effect with Allopurinol and Febuxostat

Action Mechanisms and Interaction of Two Key Xanthine Oxidase Inhibitors in Galangal: Combination of in Vitro and in Silico Molecular Docking Studies.

A possible covalent xanthine oxidase inhibitor TS10: Inhibition mechanism, metabolites identification and PDPK assessment

Exploration of Novel Non-Purine Xanthine Oxidase Inhibitors Based on Oxadiazolones by an Integrated Simulation Study

Synthesis and Biological Evaluation of Thiazolidine-2-thione Derivatives As Novel Xanthine Oxidase Inhibitors.

Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia